Avaxia doses first patient in ulcerative colitis drug study

Clinical-stage biopharmaceutical company Avaxia Biologics has dosed the first patient in a Phase Ib clinical study of its gut-targeted anti-TNF antibody, for the treatment of ulcerative colitis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news